2025
Evaluating the Effect of Epigallocatechin Gallate (EGCG) in Reducing Folate Levels in Reproductive Aged Women by MTHFR and DHFR Genotype in Combination With Letrozole or Clomiphene
Johnson J, Siblini H, Al‐Hendy A, Segars J, González F, Taylor H, Singh B, Carson S, Christman G, Huang H, Dangi B, Zhang H. Evaluating the Effect of Epigallocatechin Gallate (EGCG) in Reducing Folate Levels in Reproductive Aged Women by MTHFR and DHFR Genotype in Combination With Letrozole or Clomiphene. Clinical And Translational Science 2025, 18: e70189. PMID: 40077973, PMCID: PMC11903501, DOI: 10.1111/cts.70189.Peer-Reviewed Original ResearchConceptsEpigallocatechin-3-gallateFolate levelsUterine fibroidsClinical trialsGreen tea extractAssociated with folate deficiencyPresence of MTHFRWomen of Childbearing AgeSerum folate levelsReduced folate levelsActive clinical trialsReproductive-age womenEffect of epigallocatechin gallateDHFR genotypeDHFR polymorphismTea extractDaily doseClomiphene citrateUnexplained infertilityFolate deficiencyChildbearing ageClinical studiesTreated womenFibroidsLetrozole
2024
Uterine fibroid–related infertility: mechanisms and management
Donnez J, Taylor H, Marcellin L, Dolmans M. Uterine fibroid–related infertility: mechanisms and management. Fertility And Sterility 2024, 122: 31-39. PMID: 38453041, DOI: 10.1016/j.fertnstert.2024.02.049.Peer-Reviewed Original ResearchUterine artery embolizationUterine fibroidsAssociation of fibroidsAdd-back therapyHeavy menstrual bleedingBaseline to weekOral GnRH antagonistPresence of fibroidsNon-surgical approachFocused ultrasoundFibroid volumeMyoma volumeArtery embolizationMenstrual bleedingCurrent management strategiesGnRH antagonistEchographic guidanceSurgical interventionFibroidsInfertilityMedical treatmentUterineWomenOptimal dosageSource of controversy
2023
Clinical applications of gonadotropin-releasing hormone analogues: a broad impact on reproductive medicine
Saleh F, Taylor H. Clinical applications of gonadotropin-releasing hormone analogues: a broad impact on reproductive medicine. F&S Reports 2023, 4: 83-87. PMID: 37223759, PMCID: PMC10201293, DOI: 10.1016/j.xfre.2023.01.008.Peer-Reviewed Original ResearchHormone analogueGonadotropin-releasing hormone analogueOral GnRH antagonistCommon gynecologic conditionOvarian hormone productionClinical applicationGnRH antagonistPituitary responseGnRH activityGnRH analoguesGynecologic conditionsTreatment optionsGonadal axisReproductive axisRapid onsetGynecologic practiceHormone productionReproductive medicineReproductive technologiesDiverse clinical applicationsGonadotropinEndometriosisFibroidsGnRHAntagonist
2022
Linzagolix With and Without Hormonal Add-Back Therapy for the Treatment of Symptomatic Uterine Fibroids: Two Randomized, Placebo-Controlled, Phase 3 Trials
Donnez J, Taylor H, Stewart E, Bradley L, Marsh E, Archer D, Al-Hendy A, Petraglia F, Watts N, Gotteland J, Bestel E, Terrill P, Loumaye E, Humberstone A, Garner E. Linzagolix With and Without Hormonal Add-Back Therapy for the Treatment of Symptomatic Uterine Fibroids: Two Randomized, Placebo-Controlled, Phase 3 Trials. Obstetrical & Gynecological Survey 2022, 77: 741-742. DOI: 10.1097/ogx.0000000000001113.Peer-Reviewed Original ResearchIncidence of Alopecia in Treatment of Women With Uterine Fibroids: Results of Two Phase 3 Trials of Linzagolix [A104]
Al-Hendy A, Taylor H, Catherino W, Stewart E, Bestel E, Garner E. Incidence of Alopecia in Treatment of Women With Uterine Fibroids: Results of Two Phase 3 Trials of Linzagolix [A104]. Obstetrics And Gynecology 2022, 139: 30s-30s. DOI: 10.1097/01.aog.0000826736.08037.1b.Peer-Reviewed Original ResearchPhase 3 trialUterine fibroidsGnRH antagonistHair lossPlacebo-controlled phase 3 trialUterine fibroid-related symptomsFibroid-related symptomsIncidence of alopeciaOral GnRH antagonistPooled safety analysisTreatment of womenConcomitant therapyTreatment discontinuationStudy drugWeek 52Mild alopeciaWeek 24Benign disorderSimilar incidenceLinzagolixSuppression dosesAlopeciaFibroidsTrialsTreatment
2021
EPIGALLOCATECHIN GALLATE (EGCG) FOR TREATMENT OF UNEXPLAINED INFERTILITY ASSOCIATED WITH UTERINE FIBROIDS (PRE-FRIEND TRIAL): EARLY SAFETY ASSESSMENT
Siblini H, Al-Hendy A, Segars J, Singh B, Taylor H, Flores V, González F, Christman G, Johnson J, Huang H, Zhang H. EPIGALLOCATECHIN GALLATE (EGCG) FOR TREATMENT OF UNEXPLAINED INFERTILITY ASSOCIATED WITH UTERINE FIBROIDS (PRE-FRIEND TRIAL): EARLY SAFETY ASSESSMENT. Fertility And Sterility 2021, 116: e318-e319. DOI: 10.1016/j.fertnstert.2021.07.857.Peer-Reviewed Original Research
2020
EFFICACY AND SAFETY OF LINZAGOLIX (LGX) FOR THE TREATMENT OF HEAVY MENSTRUAL BLEEDING (HMB) DUE TO UTERINE FIBROIDS (UF): RESULTS FROM TWO PHASE 3 RANDOMIZED CLINICAL TRIALS
Stewart E, Taylor H, Taylor R, Donnez J, Bestel E, Gotteland J, Humberstone A, Garner E. EFFICACY AND SAFETY OF LINZAGOLIX (LGX) FOR THE TREATMENT OF HEAVY MENSTRUAL BLEEDING (HMB) DUE TO UTERINE FIBROIDS (UF): RESULTS FROM TWO PHASE 3 RANDOMIZED CLINICAL TRIALS. Fertility And Sterility 2020, 114: e522. DOI: 10.1016/j.fertnstert.2020.09.016.Peer-Reviewed Original Research
2018
166 Efficacy and Safety of Elagolix in a Subgroup of Women with Uterine Fibroids and Adenomyosis: Results from a Phase 2 Trial
Taylor H, Bedaiwy M, Lukes A, Chwalisz K, Owens C, Bradley L. 166 Efficacy and Safety of Elagolix in a Subgroup of Women with Uterine Fibroids and Adenomyosis: Results from a Phase 2 Trial. Journal Of Minimally Invasive Gynecology 2018, 25: s86-s87. DOI: 10.1016/j.jmig.2018.09.175.Peer-Reviewed Original Research741 Patient Experience and Clinical Presentation of US Women with Uterine Fibroids: Results from the First 200 Women Enrolled in a National Real-World Study
Taylor H, Liu J, Al-Hendy A, Jackson-Bey T, Bradley L, Moon K, Kerolous M. 741 Patient Experience and Clinical Presentation of US Women with Uterine Fibroids: Results from the First 200 Women Enrolled in a National Real-World Study. Journal Of Minimally Invasive Gynecology 2018, 25: s281-s282. DOI: 10.1016/j.jmig.2018.09.754.Peer-Reviewed Original ResearchEfficacy and safety of elagolix in a subgroup of women with uterine fibroids and adenomyosis: results from a phase 2 trial
Taylor H, Bedaiwy M, Lukes A, Chwalisz K, Owens C, Bradley L. Efficacy and safety of elagolix in a subgroup of women with uterine fibroids and adenomyosis: results from a phase 2 trial. Fertility And Sterility 2018, 110: e61. DOI: 10.1016/j.fertnstert.2018.07.186.Peer-Reviewed Original Research
2017
Current and Emerging Medical Treatments for Uterine Fibroids
Chwalisz K, Taylor H. Current and Emerging Medical Treatments for Uterine Fibroids. Seminars In Reproductive Medicine 2017, 35: 510-522. PMID: 29100239, DOI: 10.1055/s-0037-1606302.Peer-Reviewed Original ResearchMeSH KeywordsCombined Modality TherapyCost of IllnessDrug ApprovalDrugs, InvestigationalEvidence-Based MedicineFemaleGonadotropin-Releasing HormoneHormone AntagonistsHumansLeiomyomaLeiomyomatosisMenorrhagiaQuality of LifeReceptors, ProgesteroneUnited StatesUnited States Food and Drug AdministrationUterine NeoplasmsConceptsUterine fibroidsMedical therapyMedical treatmentOral gonadotropin-releasing hormone antagonistLong-term medical therapyGonadotropin-releasing hormone antagonistCommon uterine neoplasmPressure-related symptomsHeavy menstrual bleedingProgesterone receptor modulatorsRandomized clinical trialsSymptomatic uterine fibroidsUnited States FoodMenstrual bleedingUterine neoplasmsSymptom managementSurgical interventionHormone antagonistClinical trialsReceptor modulatorsMedical optionsEffective treatmentClinical developmentFibroidsDrug Administration
2014
Uterine Fibroids: Clinical Manifestations and Contemporary Management
Doherty L, Mutlu L, Sinclair D, Taylor H. Uterine Fibroids: Clinical Manifestations and Contemporary Management. Reproductive Sciences 2014, 21: 1067-1092. PMID: 24819877, DOI: 10.1177/1933719114533728.Peer-Reviewed Original ResearchConceptsMedical therapyUterine fibroidsGrowth factorAbnormal uterine bleedingHeavy menstrual bleedingInterventional radiological proceduresEndometrial effectsUterine bleedingMenstrual bleedingMedical managementSurgical managementCommon lesionsCurrent armamentariumFibroid treatmentClinical trialsEffective treatmentFibroidsRadiological proceduresDrug AdministrationFibroid cellsNovel therapeuticsAbnormal regulationTherapyFibroid biologyMolecular changes
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply